Dendritic Cell Vaccines for Breast Cancer

Our laboratory has previously shown loss of HER-2 Th1 immune responses in HER-2 positive breast cancer patients versus healthy adult women.  This loss of immune response is associated with less responsiveness to currently available therapies and correlates with poor clinical prognosis in patients. Administration of HER2 dendritic cell vaccine has been shown to restore this immune response in HER2 positive breast cancer patients. Our lab monitors the immune responses of patients throughout treatment to help better understand the importance of HER-2 Th1 immune responses during treatment and to help further develop cellular therapies for breast cancer. We are currently developing a vaccine  to  generate  CD4 Th1 immune response  to other oncodrivers  such as c-MET, EGFR, MUC1 and HER3. These oncodrivers are critical to breast cancer cell proliferation and survival in different breast cancer subtypes.

Discovery MHC Class II Peptides Derived from Oncodrivers

 The identification of immunogenic epitopes from tumor antigens has become crucial in the creation of epitope-based therapeutic and preventive vaccines. Computer-based algorithms have allowed for the identification of sequence motifs capable of binding to MHC-I and II molecules to predict the existence of CD8 and CD4 T cell epitopes within the sequences of known tumor antigens. While MHC class I prediction algorithms have shown success in identifying immunogenic class I epitopes, limited success has been seen in the identification of MHC class II epitopes. The peptide screening methodology developed in our laboratory gives a novel experimental approach for the identification of promiscuous class II epitopes. Sensitization of mature DC1s with an overlapping tumor-antigen derived peptide library allows for the identification of immunogenic peptide sequences with the ability to stimulate antigen-specific CD4+ Th1 immune responses.


Intratumoral DC1 Immunobiology, the Abscopal effect, and the Connection Between Cellular and Humoral Anti-Tumor Immune Response

Intratumoral immunotherapy aims at generating priming of anti-tumor immunity to drive systemic and durable clinical benefit.  Key clinical results with intratumoral immunotherapy using  intratumoral BCG, cytokine IL-2 and immunostimulatory toll-like receptor agonists have shown both local and distant activity which indicate that there is a direct connection between the abscopal effect and mechanisms involving the immune system. Our lab is currently investigating the intratumoral delivery of DC1 vaccine to generate priming of anti-oncodriver CD4 Th1 immunity to induce systemic changes at the cellular and humoral level. In addition, we are studying the interplay between B cell antibodies and T and B cell infiltration into the tumor and their contribution to the abscopal effect.


Adoptive T Cell Therapy

While survival in patients with early HER2+ invasive breast cancer (IBC) has improved as a result of HER2 targeted agents, patients with metastatic HER2 breast cancer (MBC) often become resistant to therapy and eventually recur. Thus, there is a strong need for novel approaches to treat metastatic HER2+ BC. We have demonstrated that in patients with recurrence there is a loss of anti-HER2 CD4 Th1 response and have shown that Th1 cytokines cause induction of tumor senescence and apoptosis in HER2 IBC, especially when combined with anti-HER2 antibodies.  We have assessed whether anti-HER2 CD4 Th1 therapy induced by dendritic cells could be improved using  preclinical metastatic HER2 mouse models. We have developed a protocol to expand CD4 T cells from PBMC post DC vaccination and are currently investigating the adoptive T cell therapy approach using CD4+ T cells in preclinical murine models. In addition, we are validating different methodologies for the expansion of T cells ex vivo and for improving the homing, persistence and cytotoxicity of reinfused T cells. The goal of these strategies is to improve the clinical success of adoptive T cell therapy. 


Anti-oncodriver Th1 immunity to target disseminated cancer cells

Metastatic spread in breast cancer patients is the major driver of cancer related death. A unique subset of cells disseminated from early stage breast cancer patients act as an intermediary in the metastasis outgrowth process. Approximately 40% of early stage breast cancer patients are positive for disseminated cancer cells (DCCs) in distant organs. After dissemination, DCCs enters a dormancy stage and become refractory to conventional therapies. After a prolonged period of time, these DCCs get activated and can form overt metastasis. DCCs exhibits heterogenic characteristics, stem cell like properties and express unique gene signatures, which makes them difficult to target with current therapies. Our laboratory focuses on understanding the molecular mechanisms of breast cancer cell dissemination and gene expression signatures during breast cancer progression. In addition, we are currently investigating the role of anti-oncodriver Th1 immunity. and targeted therapy on DCCs and their effect on stemness/dormancy potential and tumor recurrence/metastasis seeding potential.





Th1 immune response and ubiquitin proteosomal pathways to target breast cancer cells

HER2-targeted agents improve survival in early breast cancer (BC), but for patients with locally advanced or metastatic disease, therapy resistance remains a significant clinical problem.  HER2 overexpression can be maintained because proteasomal degradation pathway (PDP) E3 ubiquitin ligase Cullin5 (CUL5), which targets proteins to PDP, is frequently mutated or under expressed, resulting in reduced overall survival for HER2 BC patients. Protection from CUL5 also occurs when client proteins associate with the co-chaperones cell division cycle 37 (Cdc37) and heat shock protein 90 (Hsp90).  We are currently investigating the relationship between PDP/ HER2 targeted therapy, and the Th1 immune response in HER2 sensitive and resistant cells.

Immunotherapy for TNBC

Triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer and demands novel therapeutic strategy for better efficacy and improved patient outcome. One of the primary interests in our lab is to understand the molecular architecture of triple negative tumors and to develop an effective and targeted immunotherapy for TNBC patients. Breast cancer cells have multiple proteins known as oncodrivers, which play a critical role in tumor cell growth and proliferation.  Developing new cancer therapies targeting these oncodriver proteins and their signaling pathways has been a promising area of translational cancer research.


Microbiome and Breast Cancer

Apart from inherited susceptibility such as BRCA mutations, several environmental factors and lifestyle components have also been strongly linked to breast cancer. Epidemiologic studies suggest that the human microflora contributes to 16–18% or more of worldwide malignancies. Microbiota of women with breast cancer differs from that of healthy women, indicating that certain bacteria may be associated with cancer development and in response to therapy. Our laboratory is currently investigating how the gut microbiome contributes to both breast cancer growth and survival through reciprocal interaction with the immune response.